While there are limited preclinical GBM data on TIM-3 blockade, Kim’s group demonstrated a novel triple glioma therapy that combined dual TIM-3 and PD-1 blockade with stereotactic radiosurgery, showing a significant improvement in OS [112]. The gene discussed is HAVCR2; the disease is central nervous system cancer.